On Oct. 8, 2020, SIGA Technologies announced that the Public Health Agency of Canada (PHAC) has issued an advanced contract award notice, indicating that the PHAC intends to purchase up to 33,300 courses of oral TPOXXﾮ (tecovirimat) within five years.

TPOXXﾮ, also known as tecovirimat and ST-246ﾮ, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus.